Metabotropic Glutamate (mGluR) Receptor Neurons

Metabotropic Glutamate Receptor Neurons

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Metabotropic Glutamate (mGluR) Receptor Neurons</th>
</tr>
<tr>
<td class="label">Taxonomy</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology (CL)</td>
<td>[CL:0000197](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000197)</td>
</tr>
<tr>
<td class="label">Disease</td>
<td>mGluR Pathology</td>
</tr>
<tr>
<td class="label">Alzheimer disease</td>
<td>mGluR5-Aβ interaction, calcium dysregulation</td>
</tr>
<tr>
<td class="label">Parkinson disease</td>
<td>mGluR5-mediated STN hyperactivity</td>
</tr>
<tr>
<td class="label">Huntington disease</td>
<td>Striatal mGluR5 upregulation, excitotoxicity</td>
</tr>
<tr>
<td class="label">ALS</td>
<td>Cortical mGluR dysfunction, motor neuron death</td>
</tr>
<tr>
<td class="label">Stroke</td>
<td>Peri-infarct mGluR5 activation</td>
</tr>
</table>

Overview

Metabotropic Glutamate Receptor Neurons

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Metabotropic Glutamate (mGluR) Receptor Neurons</th>
</tr>
<tr>
<td class="label">Taxonomy</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology (CL)</td>
<td>[CL:0000197](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000197)</td>
</tr>
<tr>
<td class="label">Disease</td>
<td>mGluR Pathology</td>
</tr>
<tr>
<td class="label">Alzheimer disease</td>
<td>mGluR5-Aβ interaction, calcium dysregulation</td>
</tr>
<tr>
<td class="label">Parkinson disease</td>
<td>mGluR5-mediated STN hyperactivity</td>
</tr>
<tr>
<td class="label">Huntington disease</td>
<td>Striatal mGluR5 upregulation, excitotoxicity</td>
</tr>
<tr>
<td class="label">ALS</td>
<td>Cortical mGluR dysfunction, motor neuron death</td>
</tr>
<tr>
<td class="label">Stroke</td>
<td>Peri-infarct mGluR5 activation</td>
</tr>
</table>

Overview

Metabotropic glutamate receptor (mGluR) neurons express members of the mGluR family (GRM1-8), which are G protein-coupled receptors that modulate synaptic transmission, neuronal excitability, and plasticity. Unlike ionotropic glutamate receptors (NMDA, AMPA, kainate), mGluRs produce slower, modulatory effects via second messenger cascades. Dysregulation of mGluR signaling contributes to excitotoxicity in stroke, Alzheimer disease, Parkinson disease, ALS, and Huntington disease, making these receptors important therapeutic targets.

<!-- multi-taxonomy-enrichment -->

Multi-Taxonomy Classification

Taxonomy Database Cross-References

External Database Links

• [Cell Ontology (CL:0000197)](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000197)
• [OBO Foundry (CL:0000197)](http://purl.obolibrary.org/obo/CL_0000197)
• [Allen Brain Cell Atlas](https://portal.brain-map.org/atlases-and-data/bkp/abc-atlas)
• [CellxGene Census](https://cellxgene.cziscience.com/)
• [Human Cell Atlas](https://www.humancellatlas.org/)

Neuroanatomy

Group I mGluRs (mGluR1, mGluR5)

Group I mGluRs are predominantly postsynaptic and mediate excitatory modulation[@niswender2010]:

mGluR1 (GRM1):

• High expression: Cerebellar Purkinje cells, hippocampus, thalamus, substantia nigra
• Location: Perisynaptic annulus around postsynaptic density
• Function: Synaptic plasticity (LTD in cerebellum), motor learning

• High expression: Cortex, hippocampus, striatum, nucleus accumbens
• Location: Perisynaptic and extrasynaptic
• Function: Synaptic plasticity (LTP), cognition, reward processing

Group II mGluRs (mGluR2, mGluR3)

Group II mGluRs are primarily presynaptic autoreceptors that inhibit glutamate release[@schoepp2001]:

mGluR2 (GRM2):

• Expression: Presynaptic terminals in cortex, hippocampus, thalamus
• Function: Feedback inhibition of glutamate release, suppression of excitotoxicity

• Expression: Presynaptic terminals and glial cells
• Function: Modulation of glutamate uptake, anti-inflammatory effects in astrocytes

Group III mGluRs (mGluR4, mGluR6, mGluR7, mGluR8)

Group III mGluRs are presynaptic receptors that inhibit neurotransmitter release[@flor2008]:

mGluR4 (GRM4):

• Expression: Cerebellum, hippocampus, striatum, pallidum
• Function: Motor control, cerebellar LTD, modulates GABA release in basal ganglia

• Expression: Retinal ON bipolar cells (exclusive)
• Function: ON pathway signal transduction via TRPM1 channel closure

• Expression: Widely distributed, high in hippocampus and cortex
• Function: Low-affinity receptor activated during high-frequency transmission

• Expression: Hippocampus, olfactory bulb, retina
• Function: Anxiety modulation, retinal processing

Molecular Biology

Receptor Structure

mGluRs are class C GPCRs with a unique architecture[@pin2016]:

• Venus flytrap domain (VFT): Extracellular N-terminal domain that binds glutamate
• Cysteine-rich domain: Connects VFT to transmembrane domain
• 7-transmembrane domain (7TM): Classic GPCR structure that binds allosteric modulators
• C-terminal tail: Variable length; mediates protein interactions and trafficking

Activation and Signaling

Glutamate binding: Occurs in the VFT domain, which closes around the ligand like a Venus flytrap. This conformational change is transmitted through the cysteine-rich domain to the 7TM.

Dimerization: mGluRs function as obligate dimers. Ligand binding stabilizes the active dimeric conformation.

G protein coupling: Group I receptors couple to Gq/11; Group II and III receptors couple to Gi/o.

Allosteric modulation: Positive allosteric modulators (PAMs) and negative allosteric modulators (NAMs) bind to the 7TM domain and modulate receptor function without directly activating it.

Desensitization and Regulation

GRK phosphorylation: G protein-coupled receptor kinases (GRKs) phosphorylate activated mGluRs, leading to β-arrestin recruitment and internalization.

PKC feedback: Protein kinase C phosphorylates Group I mGluRs, reducing their responsiveness (homologous desensitization).

Homer proteins: Scaffold proteins that link mGluR5 to intracellular calcium stores and regulate receptor trafficking.

Disease Associations

Excitotoxicity and Neurodegeneration

Excessive mGluR activation contributes to excitotoxic neuronal death in multiple conditions[@wang2017]:

Mechanism: Group I mGluR activation can potentiate NMDA receptor currents and increase intracellular calcium, triggering apoptotic and necrotic cell death pathways.

Parkinson Disease

In PD, loss of dopaminergic input to the striatum leads to overactivity of the indirect pathway via D2 receptor loss. mGluR5 antagonists can reduce this overactivity[@johnston2018]:

• mGluR5 NAMs: Mavoglurant (AFQ056), dipraglurant reduce levodopa-induced dyskinesias in animal models
• mGluR4 PAMs: Enhance activity of receptors that inhibit GABA release in globus pallidus externa, normalizing basal ganglia output

Alzheimer Disease

mGluR5 interacts with amyloid-β oligomers and contributes to their toxic effects[@hamilton2017]:

• Aβ-mGluR5 binding: Aβ oligomers activate mGluR5, leading to calcium dysregulation and tau hyperphosphorylation
• mGluR5 NAMs: May reduce Aβ toxicity and improve cognitive function
• Fragile X connection: mGluR5 hyperactivity in fragile X syndrome (FMRP loss) shares mechanisms with AD

ALS

Group II mGluR agonists may protect motor neurons by reducing cortical glutamate release[@remke2016]:

• Reduced excitotoxicity: Presynaptic inhibition of glutamate release limits overactivation of motor neuron AMPA/NMDA receptors
• Glia-mediated protection: mGluR3 activation on astrocytes promotes glutamate uptake and anti-inflammatory responses

Psychiatric Disorders

Anxiety/depression: mGluR2/3 agonists (e.g., pomaglumetad) showed efficacy in preclinical models but mixed results in clinical trials

Schizophrenia: mGluR2/3 agonists may reduce psychosis via suppression of cortical glutamate release

Addiction: mGluR5 antagonists reduce reward-seeking behavior in preclinical models

Therapeutic Approaches

Allosteric Modulators

Advantages over orthosteric ligands:

• Greater receptor subtype selectivity (7TM domains more divergent than VFT domains)
• Preserve spatial and temporal patterns of receptor activation
• Failsafe mechanism—only modulate naturally active receptors

• Mavoglurant (AFQ056): PD levodopa-induced dyskinesias (Phase II)
• Dipraglurant: PD dyskinesias (Phase II)
• Fenobam: Anxiety, fragile X (historical)

• ADX88178: PD motor symptoms (Phase I)
• Foliglurax: PD dyskinesias and motor symptoms (preclinical)

• Pomaglumetad (LY2140023): Schizophrenia (Phase III failed)
• MGS0028: Anxiety, depression (preclinical)

Retinal Therapeutics

mGluR6 is essential for ON bipolar cell signaling. In congenital stationary night blindness with GRM6 mutations, gene therapy approaches are under investigation[@zeitz2014].

Clinical Evaluation

Neuroimaging

• PET imaging: 11CABP688 and 18FFPEB ligands for mGluR5 allow quantification in living brain
• fMRI: mGluR modulation affects BOLD signal in cortex and striatum

Biomarkers

• CSF glutamate: Elevated in ALS, may predict progression
• Blood BDNF: Modulated by mGluR5 activity; reduced in depression and AD

Cross-Links

• Glutamate Neurotransmission
• [Excitotoxicity](/mechanisms/excitotoxicity)
• [NMDA Receptors](/mechanisms/glutamatergic-signaling)
• [Cerebellar Purkinje Cells](/cell-types/cerebellar-purkinje-cells)
• [Striatal Medium Spiny Neurons](/cell-types/striatal-medium-spiny-neurons)

See Also

• [Neurons — Major brain cell type
• Glia — Support cells in the brain](/cell-types/neurons-—-major-brain-cell-type

• [Alzheimer's Disease](/diseases/alzheimers-disease) — Related neurodegenerative disease
• [Parkinson's Disease — Related neurodegenerative disease

• [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data
• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature

Pathway Diagram

The following diagram shows the key molecular relationships involving Metabotropic Glutamate (mGluR) Receptor Neurons discovered through SciDEX knowledge graph analysis: